血蓝蛋白结构式
|
常用名 | 血蓝蛋白 | 英文名 | Hemocyanin |
---|---|---|---|---|
CAS号 | 9013-72-3 | 分子量 | N/A | |
密度 | N/A | 沸点 | N/A | |
分子式 | N/A | 熔点 | N/A | |
MSDS | 美版 | 闪点 | N/A |
血蓝蛋白用途血蓝蛋白是一种含有大量铜的呼吸蛋白。血蓝蛋白是一种重要的非特异性先天免疫防御分子,具有酚氧化酶、抗病毒、抗菌、溶血和抗肿瘤活性[1]。 |
中文名 | 二乙氨基乙基纤维素 |
---|---|
英文名 | Cellulose DEAE |
英文别名 | 更多 |
描述 | 血蓝蛋白是一种含有大量铜的呼吸蛋白。血蓝蛋白是一种重要的非特异性先天免疫防御分子,具有酚氧化酶、抗病毒、抗菌、溶血和抗肿瘤活性[1]。 |
---|---|
相关类别 | |
靶点 |
Human Endogenous Metabolite |
参考文献 |
储存条件 | 2-8°C密闭、阴凉干燥处 |
---|---|
稳定性 | Biochem/physiol Actions Highly soluble carrier protein used in antibody production Physical form Solution in 0.15 M NaCl, 0.05 M sodium phosphate, pH 7.2, and 50% glycerol. Legal Information Blue Carrier is a registered trademark of Biosonda S.A. |
更多 | 1. 性状:未确定。 2. 密度(g/mL,25℃):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):未确定 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,5.2kPa):未确定 7. 折射率:未确定 8. 闪点(ºC):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(kPa,20ºC):未确定 12. 饱和蒸气压(kPa,60ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:溶于水 |
Binding of WIP to actin is essential for T cell actin cytoskeleton integrity and tissue homing.
Mol. Cell. Biol. 34(23) , 4343-54, (2014) The Wiskott-Aldrich syndrome protein (WASp) is important for actin polymerization in T cells and for their migration. WASp-interacting protein (WIP) binds to and stabilizes WASp and also interacts wit... |
|
Identification and characterization of the related immune-enhancing proteins in crab Scylla paramamosain stimulated with rhubarb polysaccharides.
Mol. Immunol. 57(2) , 263-73, (2014) Recently, considerable interest has been focused on immunostimulants to reduce diseases in crab aquaculture. However, information regarding to the related immune-enhancing proteins in crabs is not ava... |
|
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
J. Immunol. 193(1) , 48-55, (2014) Immunogenicity remains the "Achilles' heel" of protein-based therapeutics. Anti-drug Abs produced in response to protein therapeutics can severely limit both the safety and efficacy of this expanding ... |
MFCD00131280 |